Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOFACITINIB Cause Systemic lupus erythematosus? 5,656 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 5,656 reports of Systemic lupus erythematosus have been filed in association with TOFACITINIB (XELJANZ XR). This represents 3.6% of all adverse event reports for TOFACITINIB.

5,656
Reports of Systemic lupus erythematosus with TOFACITINIB
3.6%
of all TOFACITINIB reports
1,636
Deaths
2,203
Hospitalizations

How Dangerous Is Systemic lupus erythematosus From TOFACITINIB?

Of the 5,656 reports, 1,636 (28.9%) resulted in death, 2,203 (38.9%) required hospitalization, and 1,913 (33.8%) were considered life-threatening.

Is Systemic lupus erythematosus Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOFACITINIB. However, 5,656 reports have been filed with the FAERS database.

What Other Side Effects Does TOFACITINIB Cause?

Drug ineffective (30,382) Pain (21,659) Condition aggravated (16,925) Arthralgia (15,640) Fatigue (13,551) Rheumatoid arthritis (12,277) Off label use (11,736) Headache (11,061) Joint swelling (10,686) Malaise (9,040)

What Other Drugs Cause Systemic lupus erythematosus?

ADALIMUMAB (11,880) METHOTREXATE (9,350) INFLIXIMAB (9,071) ABATACEPT (8,944) HYDROXYCHLOROQUINE (8,867) RITUXIMAB (8,819) PREDNISONE (8,799) LEFLUNOMIDE (8,669) TOCILIZUMAB (8,656) FOLIC ACID (8,360)

Which TOFACITINIB Alternatives Have Lower Systemic lupus erythematosus Risk?

TOFACITINIB vs TOFERSEN TOFACITINIB vs TOLNAFTATE TOFACITINIB vs TOLODODEKIN ALFA TOFACITINIB vs TOLTERODINE TOFACITINIB vs TOLVAPTAN

Related Pages

TOFACITINIB Full Profile All Systemic lupus erythematosus Reports All Drugs Causing Systemic lupus erythematosus TOFACITINIB Demographics